NASDAQ$VYGR
Voyager Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Voyager Therapeutics reported Q4 2021 financial results and provided business updates.
Voyager Therapeutics reported collaboration revenue of $28.1 million for the fourth quarter of 2021, compared to $6.5 million for the same period in 2020, with a net income of $5.7 million for the fourth quarter of 2021, compared to a net loss of $15.9 million for the same period of 2020.
- License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets
- Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER technology following October 2021 Pfizer agreement
- Strengthened leadership with appointment of Al Sandrock, Jr., M.D., Ph.D. to Board of Directors and Board Executive Committee, promotion of Robin Swartz to chief operating officer
- Cash runway extended into 2024 with $84 million aggregate upfront payments from Novartis and Pfizer transactions
Headline financials
Revenue & EPS history
Voyager Therapeutics · Revenue · Quarterly
$28.1M
Revenue by segment
Voyager Therapeutics · $28.1M total across 1 segment · Q4 2021
- Collaboration Revenue$28.1M+329.9%100.0%
Forward guidance
Voyager expects that its cash, cash equivalents, and marketable securities inclusive of upfront payments anticipated to be received under the Novartis license option agreement will be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+2.3%
Avg return
30 days after
45%
19 / 42 earnings
Positive
+60.3%
Q4 2021
Best reaction
-21.7%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -0.5% | — | |
| Q4 2025 | +21.7% | +8.5% | -3.6% | |
| Q3 2025 | +0.0% | -7.7% | +3.5% | |
| Q1 2025 | +0.0% | -9.4% | +0.3% | |
| Q4 2024 | +2.3% | -2.0% | -20.2% | |
| Q3 2024 | -4.6% | -19.5% | -10.8% | |
| Q2 2024 | -11.7% | -13.2% | -20.5% | |
| Q1 2024 | -1.5% | -1.1% | -1.8% | |
| Q4 2023 | -6.6% | +8.2% | +4.5% | |
| Q3 2023 | +1.6% | -5.4% | +13.4% | |
| Q2 2023 | -1.7% | -1.2% | +12.2% | |
| Q1 2023 | +19.0% | +25.6% | +53.9% | |
| Q4 2022 | +2.1% | -5.5% | +0.4% | |
| Q3 2022 | +6.5% | +14.6% | +25.7% | |
| Q2 2022 | -2.0% | -13.6% | -6.4% | |
| Q1 2022 | -18.4% | -38.0% | -23.9% | |
| Q4 2021 | +60.3% | +42.2% | +129.8% | |
| Q3 2021 | +7.5% | +2.4% | -21.0% | |
| Q2 2021 | +10.4% | -3.1% | +4.7% | |
| Q1 2021 | +2.1% | +5.6% | +9.1% | |
| Q4 2020 | -14.0% | -14.0% | -26.9% | |
| Q3 2020 | -21.7% | -22.1% | -28.1% | |
| Q2 2020 | +0.1% | +0.7% | -6.8% | |
| Q1 2020 | -5.9% | +8.0% | +4.9% | |
| Q4 2019 | +6.6% | -3.3% | -23.3% | |
| Q3 2019 | -2.6% | -5.0% | -5.9% | |
| Q2 2019 | -2.8% | +2.3% | -21.1% | |
| Q1 2019 | +1.9% | +1.6% | -4.3% | |
| Q4 2018 | +11.5% | +19.0% | +37.0% | |
| Q3 2018 | -9.6% | -15.6% | -21.3% | |
| Q2 2018 | -15.7% | -10.5% | -3.6% | |
| Q1 2018 | -4.3% | +8.0% | +17.6% | |
| Q4 2017 | -9.9% | -13.2% | -22.7% | |
| Q3 2017 | -17.5% | -34.6% | -29.5% | |
| Q2 2017 | +6.6% | +4.3% | +71.7% | |
| Q1 2017 | +6.1% | +4.0% | -0.1% | |
| Q4 2016 | -1.9% | -0.3% | -2.5% | |
| Q3 2016 | +2.9% | +17.3% | +21.4% | |
| Q2 2016 | +3.0% | +2.8% | -18.3% | |
| Q1 2016 | -6.5% | — | — | |
| Q4 2015 | -7.2% | — | — | |
| Q3 2015 | +9.2% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro